Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes

Abstract EN

To investigate effects of long-term testosterone (T) therapy in obese men with T deficiency (TD) and type 2 diabetes mellitus (T2DM), data were collected from two observational, prospective, and cumulative registry studies of 561 men with TD receiving T therapy for up to 6 years.

A subgroup of obese hypogonadal men with T2DM was analyzed.

Weight, height, waist circumference (WC), fasting blood glucose (FBG), glycated haemoglobin ( HbA 1c ) blood pressure, lipid profile, C-reactive protein (CRP), and liver enzymes were measured.

A total of 156 obese, diabetic men with T deficiency, aged 61.17 ± 6.18 years, fulfilled selection criteria.

Subsequent to T therapy, WC decreased by 11.56 cm and weight declined by 17.49 kg (15.04%).

Fasting glucose declined from 7.06 ± 1.74 to 5.59 ± 0.94 mmol/L ( P < 0.0001 for all).

HbA 1c decreased from 8.08 to 6.14%, with a mean change of 1.93%.

Systolic and diastolic blood pressure, lipid profiles including total cholesterol: HDL ratio, CRP, and liver enzymes all improved ( P < 0.0001 ).

Long-term T therapy for up to 6 years resulted in significant and sustained improvements in weight, T2DM, and other cardiometabolic risk factors in obese, diabetic men with TD and this therapy may play an important role in the management of obesity and diabetes (diabesity) in men with T deficiency.